The company has substantially improved the progress of an novel solution for ATTR-CM, leveraging the investigational drug. Preliminary trial data indicates promising improvements for those suffering by a serious https://attrcm971408.educationalimpactblog.com/63721209/bridgebio-advances-cardiac-amyloidosis-management-through-attruby